Back to Search Start Over

Determinants of Anti-S Immune Response at 12 Months after SARS-CoV-2 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project

Authors :
Ludovica Leomanni
Giulia Collatuzzo
Emanuele Sansone
Emma Sala
Giuseppe De Palma
Stefano Porru
Gianluca Spiteri
Maria Grazia Lourdes Monaco
Daniela Basso
Sofia Pavanello
Maria Luisa Scapellato
Francesca Larese Filon
Luca Cegolon
Marcella Mauro
Vittorio Lodi
Tiziana Lazzarotto
Ivan Noreña
Christina Reinkemeyer
Le Thi Thu Giang
Eleonóra Fabiánová
Jozef Strhársky
Marco Dell’Omo
Nicola Murgia
Lucía A. Carrasco-Ribelles
Concepción Violán
Dana Mates
Agripina Rascu
Luigi Vimercati
Luigi De Maria
Shuffield S. Asafo
Giorgia Ditano
Mahsa Abedini
Paolo Boffetta
Source :
Vaccines, Vol 11, Iss 10, p 1527 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

Background: The effectiveness of the immunity provided by SARS-CoV-2 vaccines is an important public health issue. We analyzed the determinants of 12-month serology in a multicenter European cohort of vaccinated healthcare workers (HCW). Methods: We analyzed the sociodemographic characteristics and levels of anti-SARS-CoV-2 spike antibodies (IgG) in a cohort of 16,101 vaccinated HCW from eleven centers in Germany, Italy, Romania, Slovakia and Spain. Considering the skewness of the distribution, the serological levels were transformed using log or cubic standardization and normalized by dividing them by center-specific standard errors. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of one standard deviation of log or cubic antibody level and the corresponding 95% confidence interval (CI) for different factors and combined them in random-effects meta-analyses. Results: We included 16,101 HCW in the analysis. A high antibody level was positively associated with age (RR = 1.04, 95% CI = 1.00–1.08 per 10-year increase), previous infection (RR = 1.78, 95% CI 1.29–2.45) and use of Spikevax [Moderna] with combinations compared to Comirnaty [BioNTech/Pfizer] (RR = 1.07, 95% CI 0.97–1.19) and was negatively associated with the time since last vaccine (RR = 0.94, 95% CI 0.91–0.98 per 30-day increase). Conclusions: These results provide insight about vaccine-induced immunity to SARS-CoV-2, an analysis of its determinants and quantification of the antibody decay trend with time since vaccination.

Details

Language :
English
ISSN :
2076393X
Volume :
11
Issue :
10
Database :
Directory of Open Access Journals
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
edsdoj.7fcd9111e654f4580ac013989fc59e0
Document Type :
article
Full Text :
https://doi.org/10.3390/vaccines11101527